Development of a Bacterial Lysate from Antibiotic-Resistant Pathogens Causing Hospital Infections

Area of Science:

• Biotechnology
• Microbiology
• Immunology

Background:

• Rising antibiotic resistance in hospitals necessitates novel therapeutic strategies.
• Hospital-acquired infections pose a significant threat, requiring innovative drug development.

Purpose of the Study:

• To develop bacterial lysates from antibiotic-resistant pathogens isolated from clinical settings.
• To create a bacterial lysate consortium for potential therapeutic applications.

Main Methods:

• Isolation and identification of bacterial pathogens using morphological, cultural, biochemical, and 16S rRNA gene sequencing.
• Assessment of strain viability, antibacterial sensitivity, and inter-culture biosafety.
• Preparation of bacterial lysates using physical disruption (French press homogenizer).

Main Results:

• 25 pure isolates were obtained from 15 clinical sources, belonging to genera including *Escherichia*, *Klebsiella*, and *Pseudomonas*.
• High strain viability (10^9-10^10 CFU/mL) and inter-culture compatibility were observed.
• Three predominant pathogens (*Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*) were selected for lysate consortium development.

Conclusions:

• A bacterial lysate consortium was successfully developed from key hospital-acquired pathogens.
• The resulting lysate product has industrial value and potential for immune system stimulation.
• This approach may offer a novel strategy to combat respiratory pathogens in healthcare settings, particularly in Kazakhstan.